KDR and renal cell carcinoma: Since the discovery of the VEGF/VEGFR signaling pathway as a master regulator of angiogenesis in development and pathology, clinical translation of anti-VEGF/VEGFR drugs has been extensively implemented in cancer treatment, making antiangiogenic therapies an established standard to combat tumor progression in some advanced cancers including metastatic RCC.